DNA
Ginkgo Bioworks Holdings, Inc.
There isn't enough reported data to score DNA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
DNA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
DNA's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DNA PE Valuation
DNA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect DNA's losses to grow, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
DNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.19 | +$1.90 |
| Q2 2026 | -$5.00 | +$0.72 |
| Q1 2026 | -$5.35 | +$3.67 |
| Q4 2025 | -$5.64 | +$4.90 |
| Q3 2025 | -$6.09 | +$6.59 |
| Q2 2025 | -$5.72 | +$12.28 |
| Q1 2025 | -$9.02 | +$8.18 |
| Q4 2024 | -$10.54 | +$7.86 |
DNA is still losing money, but far less than before: $4.19 per share over the past year, against $96.00 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DNA on earnings quality, reporting a profit while its opponent remains loss making.
DNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.7M | -29% |
| Q2 2026 | $20.2M | -59% |
| Q1 2026 | $19.5M | -60% |
| Q4 2025 | $33.4M | -24% |
| Q3 2025 | $38.8M | -56% |
| Q2 2025 | $49.6M | -12% |
| Q1 2025 | $48.3M | +27% |
| Q4 2024 | $43.8M | +26% |
DNA's revenue has slid since its 2022 peak: $28M last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -157% | +74 points |
| Q2 2026 | -290% | -158 points |
| Q1 2026 | -367% | -182 points |
| Q4 2025 | -212% | +24 points |
| Q3 2025 | -232% | -170 points |
| Q2 2025 | -132% | +265 points |
| Q1 2025 | -184% | +285 points |
| Q4 2024 | -236% | +276 points |
DNA's operating margin was −157% last quarter, up 74 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DNA on profitability, with a higher operating margin.
DNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.3M | +$1.3M |
| Q2 2026 | -$46.9M | -$6.6M |
| Q1 2026 | -$48.6M | +$10.5M |
| Q4 2025 | -$47.7M | +$8.5M |
| Q3 2025 | -$31.6M | +$87M |
| Q2 2025 | -$40.3M | +$71.1M |
| Q1 2025 | -$59.1M | +$36.8M |
| Q4 2024 | -$56.1M | +$5.1M |
DNA has burned cash in almost every quarter: −$174M over the past year, against −$187M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DNA on cash generation, producing positive trailing cash flow while its opponent burns cash.
DNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +1.9M shares |
| 1 year | +15% | +8.3M shares |
| 3 years | +31% | +15.2M shares |
| 5 years | +99% | +31.8M shares |
DNA has 64M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DNA Net Leverage
DNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.4 | Neutral |
| Stochastic | 37.8 | Neutral |
DNA's weekly RSI is 53 (neutral) and its Stochastic is 38 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DNA PE vs Healthcare Sector
DNA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.1 | 8% below |
| 20 week MA | $9.13 | 12% above |
| 50 week MA | $8.69 | 18% above |
| 100 week MA | $9.47 | 8% above |
| 200 week MA | $27.5 | 63% below |
DNA's trend is mixed: it's above three of its five weekly moving averages, and 63% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DNA on trend strength, trading above more of its moving averages.
DNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $414.8 | $426.8 | +2.9% |
| 2022 | $426.8 | $66.4 | -84% |
| 2023 | $66.4 | $67.6 | +1.8% |
| 2024 | $67.6 | $9.66 | -86% |
| 2025 | $9.66 | $8.40 | -13% |
| 2026 YTD | $8.40 | $10.2 | +22% |
DNA has finished lower in three of the last five years. It's up 22% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over DNA on returns for 2026, with the stronger performance.